Evaluation of the Safety and Efficacy of EXPAREL When Administered Into the TAP in Subjects Undergoing Cesarean Section

NCT ID: NCT02353754

Last Updated: 2021-03-26

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE4
• Total Enrollment: 12 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2015-05-31
• Study Completion Date: 2015-07-31

Brief Summary

This is a Phase 4, multicenter, open-label study evaluating EXPAREL infiltration into the transversus abdominis plane (TAP) after bupivacaine hydrochloride (HCl) spinal anesthesia in subjects undergoing elective Cesarean section (C-section).

Detailed Description

There will be two groups of subjects with approximately 40 subjects per group. Prior to the C-section, all subjects will receive single-shot spinal anesthesia (1.5 mL bupivacaine HCl 0.75% with dextrose 8.25%). Subjects in Group 1 (Standard of Care) will receive intrathecal morphine injection (e.g., Duramorph®) 0.2 mg in conjunction with the single-shot spinal anesthesia. No TAP block will be administered. Subjects in Group 2 (EXPAREL/TAP) will receive a bilateral TAP infiltration with a single 20 mL dose of EXPAREL 266 mg expanded in volume with 20 mL of normal saline for a total volume of 40 mL (20 mL infiltrated on each side of the abdomen).

Conditions

Pain

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Standard of Care

Subjects in Group 1 (Standard of Care) will receive intrathecal morphine injection (e.g., Duramorph®) 0.2 mg in conjunction with the single-shot spinal anesthesia. No TAP block will be administered.

Group Type: ACTIVE_COMPARATOR

Intrathecal morphine injection

Intervention Type: DRUG

0.2 mg

EXPAREL/TAP

Subjects in Group 2 will receive a bilateral TAP infiltration with a single 20 mL dose of EXPAREL 266 mg expanded in volume with 20 mL of normal saline for a total volume of 40 mL (20 mL infiltrated on each side of the abdomen).

Group Type: EXPERIMENTAL

EXPAREL

Intervention Type: DRUG

266 mg

Interventions

Intrathecal morphine injection

0.2 mg

Intervention Type: DRUG

EXPAREL

266 mg

Intervention Type: DRUG

Other Intervention Names

Duramorph; Bupivacaine liposome injectable suspension

Eligibility Criteria

Inclusion Criteria

1. Females ≥18 years of age at screening.

2. Scheduled to undergo elective C-section (single or multiple births).

3. American Society of Anesthesiology (ASA) physical status 1, 2, or 3.

4. Able to provide informed consent, adhere to the study visit schedule, and complete all study assessments.

Exclusion Criteria

1. History of hypersensitivity or idiosyncratic reaction to amide-type local anesthetics or opioids.

2. Contraindication to bupivacaine, morphine, ketorolac, ibuprofen, or acetaminophen.

3. Planned concurrent surgical procedure with the exception of salpingo-oophorectomy or tubal ligation.

4. Use of any of the following medications within the times specified before surgery: long-acting opioid medication, non-steroidal anti-inflammatory drugs (NSAIDs), or aspirin (except for low-dose aspirin used for cardioprotection) within 3 days, or any opioid medication or acetaminophen within 24 hours.

5. Initiation of treatment with any of the following medications within 1 month of study drug administration or if the medication(s) are being given to control pain: selective serotonin reuptake inhibitors (SSRIs), selective norepinephrine reuptake inhibitors (SNRIs), gabapentin, pregabalin (Lyrica®), or duloxetine (Cymbalta®). If a subject is taking one of these medications for a reason other than pain control, she must be on a stable dose for at least 1 month prior to study drug administration.

6. Clinically significant medical or psychiatric disease that, in the opinion of the Investigator, would constitute a contraindication to participation in the study or cause inability to comply with the study requirements.

7. History of, suspected, or known addiction to or abuse of illicit drug(s), prescription medication(s), or alcohol within the past 2 years.

8. Received an investigational drug within 30 days prior to study drug administration, and/or has planned administration of another investigational product or procedure while participating in this study.

9. Previous participating in an EXPAREL study.

The subject will be withdrawn from the study if she meets the following criteria:

10. Any clinically significant event or condition uncovered during the surgery (e.g., excessive bleeding, acute sepsis) that might render the subject medically unstable or complicate the subject's postsurgical course.

11. Her baby's 5-minute Apgar score is ≤7.

• Minimum Eligible Age: 18 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: No

Sponsors

Pacira Pharmaceuticals, Inc

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Erol Onel, MD

Role: STUDY_DIRECTOR

Pacira Pharmaceuticals, Inc

Locations

Tradition Medical Center

Port Saint Lucie, Florida, United States

University Of Minnesota

Minneapolis, Minnesota, United States

Saint Peter's University Hospital

New Brunswick, New Jersey, United States

Montefiore

The Bronx, New York, United States

The Ohio State University, Wexner Medical Center

Columbus, Ohio, United States

Countries

United States

Other Identifiers

402-C-402

Identifier Type: -

Identifier Source: org_study_id